As Technologies for Nucleotide Therapeutics Mature, Products Emerge.

ABSTRACT: The long path from initial research on oligonucleotide therapies to approval of antisense products is not unfamiliar. This lag resembles those encountered with monoclonal antibodies, gene therapies, and many biological targets and is consistent with studies of innovation showing that technology maturation is a critical determinant of product success. We previously described an analytical model for the maturation of biomedical research, demonstrating that the efficiency of targeted and biological development is connected to metrics of technology growth. The present work applies this model to characterize the advance of oligonucleotide therapeutics. We show that recent oligonucleotide product approvals incorporate technologies and targets that are past the established point of technology gro

SUBMITTER: Beierlein JM 

PROVIDER: S-EPMC5686430 | biostudies-literature | 2017 Dec

REPOSITORIES: biostudies-literature